Browse by author
Lookup NU author(s): Professor Moein MoghimiORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.PEGylation technology, that is grafting of poly(ethylene glycol)(PEG) to biologics, vaccines and nanopharmaceuticals, has become a cornerstone of modern medicines with over thirty products used in the clinic. PEGylation of therapeutic proteins, nucleic acids and nanopharmaceuticals improves their stability, pharmacokinetic and biodistribution. While PEGylated medicines are safe in the majority of patients, there are growing concerns about the emergence of anti-PEG antibodies and their impact on the therapeutic efficacy of PEGylated medicines as well as broader immune responses, particularly in complement activation and hypersensitivity reactions. These concerns are beginning to scrutinize the future viability of PEGylation technology in medicine design. Here, we outline these concerns, encourage more efforts into looking for comprehensive scientific evidence on the role of anti-PEG antibodies in hypersensitivity reactions, discuss alternatives to PEG and propose strategies for moving PEGylation technology forward.
Author(s): Simberg D, Barenholz Y, Roffler SR, Landfester K, Kabanov AV, Moghimi SM
Publication type: Note
Publication status: Published
Journal: Drug Delivery
Year: 2025
Volume: 32
Issue: 1
Online publication date: 23/04/2025
Acceptance date: 11/04/2025
ISSN (print): 1071-7544
ISSN (electronic): 1521-0464
Publisher: Taylor and Francis Ltd.
URL: https://doi.org/10.1080/10717544.2025.2494775
DOI: 10.1080/10717544.2025.2494775
PubMed id: 40264371
Data Access Statement: Data sharing is not applicable to this article as no new data were created or analyzed in this study.
